$RLFTF DD by Bert-Jan on Yh0 - From the collaborat
Post# of 653
NeuroRx shall receive 20% of Net Profits and Relief shall receive 80% of Net Profits from the Product sales in the ROW Countries.
Relief shall maintain books and records sufficient to confirm the Net Profits generated from the sales of Product in the ROW Countries consistent with GAAP.
NeuroRx shall have the right (itself or through an independent auditor) to audit Relief’s books and records to confirm the Net Profits from Relief’s sales of Product in the ROW Countries.
Should Relief request assistance from NeuroRx in clinical development, manufacture, or commercialization, NeuroRx shall be entitled to additional consideration as agreed between the Parties.